These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 19184059)

  • 1. A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer.
    Cao Y; Tan A; Gao F; Liu L; Liao C; Mo Z
    Int J Colorectal Dis; 2009 Jun; 24(6):677-85. PubMed ID: 19184059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
    Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A;
    Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
    Heinemann V; Rivera F; O'Neil BH; Stintzing S; Koukakis R; Terwey JH; Douillard JY
    Eur J Cancer; 2016 Nov; 67():11-20. PubMed ID: 27592068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-angiogenic therapies for metastatic colorectal cancer.
    Wagner AD; Arnold D; Grothey AA; Haerting J; Unverzagt S
    Cochrane Database Syst Rev; 2009 Jul; (3):CD005392. PubMed ID: 19588372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies.
    Cassidy J; Saltz LB; Giantonio BJ; Kabbinavar FF; Hurwitz HI; Rohr UP
    J Cancer Res Clin Oncol; 2010 May; 136(5):737-43. PubMed ID: 19904559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials.
    Hurwitz HI; Tebbutt NC; Kabbinavar F; Giantonio BJ; Guan ZZ; Mitchell L; Waterkamp D; Tabernero J
    Oncologist; 2013; 18(9):1004-12. PubMed ID: 23881988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
    Tappenden P; Jones R; Paisley S; Carroll C
    Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
    Sun L; Ma JT; Zhang SL; Zou HW; Han CB
    Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis.
    Botrel TEA; Clark LGO; Paladini L; Clark OAC
    BMC Cancer; 2016 Aug; 16(1):677. PubMed ID: 27558497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of bevacizumab treatment in combination with standard chemotherapy for metastatic colorectal cancer: a retrospective review of 65 Japanese patients.
    Tamiya A; Yamazaki K; Boku N; Machida N; Kojima T; Taku K; Yasui H; Fukutomi A; Hironaka S; Onozawa Y
    Int J Clin Oncol; 2009 Dec; 14(6):513-7. PubMed ID: 19967487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis.
    Li Z; Huang Y; Zhao R; Cui Y; Zhou Y; Wu X
    Sci Rep; 2018 Jan; 8(1):510. PubMed ID: 29323221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis.
    Shui L; Wu YS; Lin H; Shui P; Sun Q; Chen X
    Cell Physiol Biochem; 2018; 48(5):1870-1881. PubMed ID: 30092572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab in combination with first-line chemotherapy in patients with metastatic colorectal cancer: a meta-analysis.
    Hu W; Xu WS; Liao XF; He HJ
    Minerva Chir; 2015 Dec; 70(6):451-8. PubMed ID: 26013763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective Vascular Endothelial Growth Factor Receptor Inhibitors Provide Limited Benefits for Metastatic Colorectal Cancer: A Meta-Analysis.
    Fan Q; Lv W; Xu Y; Dong Y; Xiang Z; Wang J
    Curr Pharm Des; 2020; 26(26):3171-3186. PubMed ID: 32067605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review.
    Welch S; Spithoff K; Rumble RB; Maroun J;
    Ann Oncol; 2010 Jun; 21(6):1152-1162. PubMed ID: 19942597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Early Adverse Events on Survival Outcomes of Patients with Metastatic Colorectal Cancer Treated with Ramucirumab.
    Lim HH; Hopkins AM; Rowland A; Yuen HY; Karapetis CS; Sorich MJ
    Target Oncol; 2019 Dec; 14(6):743-748. PubMed ID: 31676953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a meta-analysis.
    Wang M; Zheng X; Ruan X; Ye B; Cai L; Lin F; Tu J; Jiang F; Li S
    Chin Med J (Engl); 2014; 127(3):538-46. PubMed ID: 24451964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of panitumumab in the treatment of patients with metastatic colorectal cancer: a meta-analysis from five randomized controlled trials.
    Liang RF; Zheng LL
    Drug Des Devel Ther; 2015; 9():4471-8. PubMed ID: 26300630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events.
    Hurwitz H; Saini S
    Semin Oncol; 2006 Oct; 33(5 Suppl 10):S26-34. PubMed ID: 17145522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials.
    Kabbinavar FF; Hurwitz HI; Yi J; Sarkar S; Rosen O
    J Clin Oncol; 2009 Jan; 27(2):199-205. PubMed ID: 19064978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.